These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6501720)

  • 1. Bromocriptine treatment of digitalis-induced ventricular tachyarrhythmias: studies in a canine model.
    Kao A; Kriett JM; Tobler HG; Detloff BL; Pritzker MR; Benson DW; Benditt DG
    J Am Coll Cardiol; 1984 Dec; 4(6):1188-94. PubMed ID: 6501720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central dopaminergic origin of bromocriptine induced tachycardia in normotensive rats.
    Lahlou S; Duarte GP; Demenge P
    Cardiovasc Res; 1993 Nov; 27(11):2022-7. PubMed ID: 8287413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist.
    Falk RH; Desilva RD; Lown B
    Cardiovasc Res; 1981 Mar; 15(3):175-80. PubMed ID: 7260985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central bromocriptine-induced tachycardia is reversed to bradycardia in conscious, deoxycorticosterone acetate-salt hypertensive rats.
    Lahlou S
    Pharmacol Toxicol; 2001 May; 88(5):238-43. PubMed ID: 11393583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine-induced tachycardia in conscious rats: blunted response following isoproterenol pretreatment for 5 days.
    Lahlou S; Duarte GP
    Acta Physiol Pharmacol Ther Latinoam; 1998; 48(3):165-74. PubMed ID: 9777039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphine suppression of digitalis-induced ventricular arrhythmias.
    Rabkin SW; Einzig S; Benditt DG
    Arch Int Pharmacodyn Ther; 1987 Oct; 289(2):267-77. PubMed ID: 3426348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats.
    Lahlou S; Lima GC; Leão-Filho CS; Duarte GP
    Can J Physiol Pharmacol; 2000 Mar; 78(3):260-5. PubMed ID: 10721819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors.
    Lahlou S; Duarte GP
    Fundam Clin Pharmacol; 1998; 12(6):599-606. PubMed ID: 9917201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 7-oxo PGI2 dramatically increases the safety margin of digitalis.
    Szilvássy Z; Szekeres L; Udvary E; Karcsu S; Végh A
    Bratisl Lek Listy; 1991; 92(3-4):134-7. PubMed ID: 2029654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How do we explain the antihypertensive effect of bromocriptine? Clinical and experimental contribution].
    Chamontin B; Montastruc JL; Rascol A
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1181-5. PubMed ID: 6151826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of verapamil on ventricular tachycardia induced by ouabain in guinea pigs.
    Goldberger JJ; Aronson RS
    Pacing Clin Electrophysiol; 1992 Feb; 15(2):162-70. PubMed ID: 1372415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal and postjunctional components in the blood pressure effects of dopamine and bromocriptine in rabbits.
    Ensinger H; Majewski H; Hedler L; Starke K
    J Pharmacol Exp Ther; 1985 Sep; 234(3):681-90. PubMed ID: 2993590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Na+/Ca2+ overload with R 56,865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs.
    Lu HR; Remeysen P; De Clerck F
    Eur J Pharmacol; 1993 Apr; 235(1):89-93. PubMed ID: 8519283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypotensive action of a dopaminergic agonist, bromocriptine, in the dog].
    Montastruc JL; Rascol A; Montastruc P
    Arch Mal Coeur Vaiss; 1981 Jun; 74 Spec No():91-8. PubMed ID: 6794532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of spinal dopamine receptors to the hypotensive action of bromocriptine in rats.
    Lahlou S; Demenge P
    J Cardiovasc Pharmacol; 1991 Sep; 18(3):317-25. PubMed ID: 1720830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R56865, an antiarrhythmic drug with class III effects that terminates ouabain induced ventricular tachycardia in an inverse rate dependent manner.
    Vos MA; van Deursen RT; Gorgels AP; Leunissen JD; Wellens HJ
    Cardiovasc Res; 1993 Aug; 27(8):1491-7. PubMed ID: 8221803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between heart rate and ouabain toxicity in the dog heart-lung preparation.
    Lahiri PK; Laddu AR
    Jpn Heart J; 1973 Jul; 14(4):357-65. PubMed ID: 4542950
    [No Abstract]   [Full Text] [Related]  

  • 18. Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats.
    Lahlou S; Araújo Lima PF; Interaminense LF; Duarte GP
    Pharmacol Toxicol; 2003 Apr; 92(4):189-94. PubMed ID: 12753422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic and hemodynamic effects of an aminosteroid (Org 3001) in the digitalized dog.
    Remme WJ; Verdouw PD; Hagemeyer F
    Eur J Pharmacol; 1976 Mar; 36(1):189-97. PubMed ID: 1261591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of ouabain-induced ventricular tachycardia in dogs with epicardial lidocaine: pharmacodynamics and functional effects.
    Sintov A; Scott WA; Gallagher KP; Levy RJ
    Pharm Res; 1990 Jan; 7(1):28-33. PubMed ID: 2300532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.